atai Life Sciences: Innovations ($ATAI (+3,45%) ) in the field of psychedelic therapies - Current successes and developments
1. successful phase 2b study on BPL-003 (5-MeO-DMT nasal spray)
On July 1, 2025 atai Life Sciences and Beckley Psytech published the topline topline results of the Phase 2b study of on BPL-003 in treatment-resistant depression. Both doses tested (8 mg and 12 mg) showed a statistically significant and clinically meaningful reduction in depression symptoms compared to a very low compared to a very low control dose - as early as on the first day day after administration, with a sustained effect until week 8. only 90 minutes after the dose discharge - a significant advance over previous psychedelic therapies with longer monitoring.stocktitan.netstatnews.com+12globenewswire.com+12ir.atai.life+12
These successes now allow the planning of Phase 3 trialsand the strategically agreed merger with Beckley Psytech can proceed to a shareholder vote in the next steps.globenewswire.com
2nd financing round: USD 50 million private placement
Also on July 1, 2025 atai announced a successful private placement in the amount of USD 50 million private placement. The round was jointly led by Ferring Ventures and Apeiron Investment Group; further investments were made by Ally Bridge Group and ADAR1. The funds will be used to finance general corporate objectives, to strengthen working capital and to further develop the clinical programs.insidermonkey.com+8nasdaq.com+8stocktitan.net+8
3. market reactions & analyst assessment
Following the publication of the trial results and the financing, the market reacted very positively:
Outlook
atai Life Sciences is on track with the progress of the BPL-003 program program, supported by solid financial resources and positive market sentiment. The planned merger with Beckley Psytech - subject to shareholder approval - is expected to further strengthen the company's profile and capabilities.
